8-K: Nano Dimension to Combine with Infinite Epigenetics

Nano Dimension Ltd. has entered into a non-binding term sheet to combine with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, aiming to create a Nasdaq-listed entity focused on chronic disease prediction and prevention.

Summary

• Nano Dimension Ltd. (Nano) has signed a non-binding term sheet to combine with Infinite Epigenetics (Infinite), an AI-powered preventive health and diagnostics company.
• The proposed transaction aims to create a publicly traded company focused on predicting, detecting, and preventing chronic diseases using epigenetics and AI.
• Infinite Epigenetics is valued at $890 million, less a 'Premium', while Nano's valuation will be based on its Net Cash plus a 20% premium and an agreed valuation for Essemtec ($20 million) and other assets.
• Existing Nano shareholders are expected to retain a meaningful minority ownership in the combined company, which will operate under the Infinite Epigenetics name and trade on Nasdaq under the ticker IEAI.
• The combined company is expected to have over $400 million in cash at closing, intended to provide ample runway without immediate need for additional capital raises.
• Nano shareholders will also receive a contingent value right (CVR) for potential future proceeds from the disposition of Nano's legacy assets.
• The transaction is subject to due diligence, negotiation of a definitive agreement, and shareholder approvals, with an expected closing by year-end.
• Infinite Epigenetics leverages a proprietary biological AI platform trained on epigenetic data, with existing revenue-generating operations through its subsidiaries TruDiagnostic and Tally Health.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as Nano Dimension is strategically pivoting its capital and public listing towards a high-growth AI healthcare sector, with a well-capitalized combined entity expected.

Positives

• Nano Dimension is deploying its capital base and Nasdaq listing into a high-growth healthcare AI opportunity.
• Infinite Epigenetics has a revenue-generating platform with over 120,000 epigenetic samples collected and a proprietary biological AI platform.
• The combined company is expected to have over $400 million in cash at closing, providing significant financial flexibility.
• The transaction is structured to provide Nano shareholders with a meaningful minority ownership in the combined entity.
• Infinite Epigenetics targets a large addressable market in chronic disease diagnostics, estimated at over $90 billion in the U.S.
• The combination aims to create a differentiated AI-powered diagnostics and preventive health platform with a durable competitive moat.
• The leadership team of Infinite Epigenetics has a strong track record of founding and scaling companies, with significant prior exit values.
• The transaction is expected to provide Infinite Epigenetics with the capital and platform to accelerate its mission and scale its operations.

Negatives

• The transaction is based on a non-binding term sheet, and there is no assurance a definitive agreement will be reached or that the transaction will be consummated.
• Nano Dimension's legacy assets and businesses not accounted for in Net Cash may not yield proceeds for shareholders via the CVR.
• The valuation of Infinite Epigenetics is $890 million less a 'Premium', the specifics of which are subject to negotiation.
• Nano shareholders will retain a 'meaningful minority ownership', the exact percentage of which is dependent on final valuations and exchange ratios.
• The transaction is subject to shareholder approval, which may not be obtained.
• There is a risk of litigation related to the transaction.
• The combined company's success is dependent on the continued development and adoption of its AI-powered epigenetic platform.
• Nano Dimension will continue to operate its remaining product lines, which may divert resources or attention from the core transaction.

Risks

• The risk that Nano Dimension and Infinite Epigenetics are unable to negotiate and enter into a definitive agreement for the Transaction.
• The risk that the conditions to the closing, including necessary shareholder approvals, are not satisfied.
• Uncertainties as to the timing of the consummation of the Transaction and the ability of each party to consummate the Transaction.
• The effect of the announcement of the Transaction on the ability of Nano Dimension and Infinite Epigenetics to continue to operate their respective businesses and retain key personnel.
• Risks related to the failure or delay in obtaining required governmental or regulatory approvals.
• Changes in the exchange ratio could cause Nano Dimension shareholders and Infinite Epigenetics stockholders to own more or less of the combined company than currently anticipated.
• The potential for the occurrence of any event, change or other circumstance that could give rise to the termination of the Term Sheet or Definitive Agreement.
• The possibility that Nano shareholders may never receive any proceeds in respect of the Legacy Assets through the CVR.

Future Outlook

The combined company, operating as Infinite Epigenetics, is expected to leverage Nano's capital base and Nasdaq listing to accelerate growth in the AI-powered preventive health and diagnostics sector. The company anticipates having over $400 million in cash at closing, providing sufficient runway to advance towards positive cash flow without immediate need for additional capital raises. The focus will be on scaling its proprietary biological AI platform, expanding commercial reach, and advancing its disease prediction and detection capabilities.

Management Comments

• "Infinite Epigenetics represented the most attractive opportunity for us to enhance shareholder value."
• "We believe Infinite Epigenetics has the potential to become a category-defining company at the intersection of healthcare, biological data and AI, and that the proposed business combination would create a clear and compelling path for long-term shareholder value creation."
• "The proposed business combination with Infinite Epigenetics represents the next major step in Nano's strategic plan."
• "We believe Infinite Epigenetics offers a compelling opportunity with meaningful long-term potential, and one that we are confident can deliver lasting value for our shareholders."
• "We believe the most valuable healthcare AI platforms will be built on proprietary biological data, leveraging AI for novel discoveries and insights."
• "Our mission is to help move healthcare from reactive to proactive by giving clinicians and individuals earlier insight into what the body is signaling, often before symptoms appear."
• "The proposed combination with Nano Dimension would provide the capital and strategic flexibility to bring these insights to people at scale."
• "This is the right opportunity at the right time. We believe Infinite is exactly the kind of AI-driven healthcare platform that can shift the market and create meaningful value for our shareholders."

Industry Context

StockSavvy.ai notes that this transaction reflects a significant trend of established companies with capital looking to pivot into high-growth sectors like AI-driven healthcare and diagnostics, seeking to leverage their public listing and financial resources. The combination with Infinite Epigenetics positions Nano Dimension within the rapidly expanding epigenetics and preventive health market, which is seeing increased investment and innovation driven by advancements in AI and data analytics.

Comparison to Industry Standards

• Exact Sciences is cited as a precedent for molecular diagnostics scaling in the public markets with a single chronic disease test.
• GRAIL is mentioned as a precedent for methylation-based disease detection from blood.
• Tempus AI is highlighted as a precedent for proprietary clinical data combined with AI creating a public-market platform.
• Infinite Epigenetics' performance metrics, such as AUCs of 0.85-0.96 for disease prediction, are presented as strong compared to published comparator ranges for existing diagnostic tools (e.g., FIB-4 for MASLD, PREVENT for CVD, FINDRISC for T2D, symptom-based case-finding for COPD).
• The company's collection of over 120,000 epigenetic samples and over 1 million epigenetic signals per test are positioned as significantly more comprehensive than standard labs measuring ~50 biomarkers.

Management Changes

Legal Proceedings

• The filing mentions the risk of litigation, including any proceedings that may be instituted against Nano Dimension or Infinite Epigenetics related to the proposed transaction.

Stakeholder Impact

• Shareholders: Expected to retain a meaningful minority ownership in the combined company, with a potential CVR for legacy assets. The transaction aims to maximize long-term shareholder value.
• Employees: Potential for integration challenges and changes in roles within the combined entity. Key personnel retention is a stated risk.
• Management: Dr. Matthew Dawson is expected to become CEO of the combined company, indicating a significant role for Infinite's leadership.
• Creditors: The filing does not explicitly detail impacts on creditors, but the financial health and cash position of the combined entity will be relevant.

Next Steps

• Negotiation and execution of a definitive merger agreement.
• Completion of confirmatory due diligence by both parties.
• Obtaining necessary Board of Directors and shareholder approvals.
• Filing of a registration statement on Form S-4.
• Obtaining regulatory approvals.
• Listing of the combined company's common stock on Nasdaq.
• Completion of Nano Dimension's re-domestication to the United States.
• Closing of the transaction, expected by the end of the year.

Key Dates

Recommendation

The transaction represents a strategic pivot for Nano Dimension into a high-growth sector, offering potential upside. However, it is based on a non-binding term sheet with significant closing conditions and risks, including shareholder approval and definitive agreement negotiation. Existing Nano shareholders will retain a minority stake, but the exact valuation and future performance are uncertain. Therefore, a 'hold' recommendation is appropriate pending the finalization and successful closing of the transaction.

Keywords

business combination, merger, Infinite Epigenetics, Nano Dimension, AI, diagnostics, epigenetics, healthcare